The estimated Net Worth of Sam Samad is at least 4.41 百万$ dollars as of 22 February 2022. Mr Samad owns over 4,561 units of Illumina Inc stock worth over 1,376,001$ and over the last 8 years he sold ILMN stock worth over 2,320,627$. In addition, he makes 716,036$ as Chief Financial Officer at Illumina Inc.
Mr has made over 10 trades of the Illumina Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 4,561 units of ILMN stock worth 569,350$ on 22 February 2022.
The largest trade he's ever made was exercising 6,626 units of Illumina Inc stock on 11 February 2020 worth over 827,124$. On average, Mr trades about 568 units every 20 days since 2017. As of 22 February 2022 he still owns at least 11,023 units of Illumina Inc stock.
You can see the complete history of Mr Samad stock trades at the bottom of the page.
Sam A. Samad is the Chief Financial Officer at Illumina Inc.
As the Chief Financial Officer of Illumina Inc, the total compensation of Mr Samad at Illumina Inc is 716,036$. There are 9 executives at Illumina Inc getting paid more, with Mostafa Ronaghi having the highest compensation of 3,541,310$.
Mr Samad is 50, he's been the Chief Financial Officer of Illumina Inc since . There are 14 older and 6 younger executives at Illumina Inc. The oldest executive at Illumina Inc is John Thompson, 71, who is the Lead Independent Director.
Sam's mailing address filed with the SEC is 500 PLAZA DRIVE, , SECAUCUS, NJ, 07094.
Over the last 21 years, insiders at Illumina Inc have traded over 412,190,379$ worth of Illumina Inc stock and bought 13,386 units worth 1,243,499$ . The most active insiders traders include John Wendell Thompson、Jay T Flatley、Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of 954,700$. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth 991,676$.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: